Brief: Portage Biotech Provides Research And Development Update
14/09/2022 14:19
Sept 14 (Reuters) - Portage Biotech Inc PRTG.O :
* PORTAGE BIOTECH PROVIDES RESEARCH AND DEVELOPMENT UPDATE
* PORTAGE BIOTECH INC - CLINICAL DEVELOPMENT GOALS FOCUSED
ON
PRODUCING PHASE 1B/PHASE 2 EFFICACY READOUTS IN MULTIPLE TUMOR
TYPES OVER NEXT TWO YEARS
* PORTAGE BIOTECH INC - HAS PREPARED PARALLEL CO-SPONSORED
STUDY,
IMPORT-201, TO BE LAUNCHED IN US, EU TO MITIGATE SLOWDOWN IN
UNITED KINGDOM
* PORTAGE BIOTECH INC - FOCUSING PRIORITIES ON CONVERTING
OUR
INVESTIGATOR-INITIATED PORT-2 STUDY INTO COMPANY-SPONSORED STUDY
* PORTAGE BIOTECH INC - FOCUSING PRIORITIES ON LAUNCHING
COMPANY-SPONSORED ADENOSINE TRIAL (PORT-6 AND PORT-7) IN US
Source text for Eikon: ID:nGNX1ddTSd
Further company coverage: PRTG.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Alpha Compute
See all newsBrief: Alpha Compute Corp. Provides Mid-Q2 2026 Update
Brief: Alpha Compute Ai Gpu Launch Update First Large-Scale Nvidia Blackwell Cluster
Brief: Alpha Compute Appoints Tom Richer To Advisory Board To Accelerate Ai Gpu Compute Infrastructure And Confidential Cloud Strategy
Brief: Alphaton Capital Rebrands As Alpha Compute Corp. To Reflect Its Growing Ai Compute Business
Brief: Alphaton Capital Announces $43 Million Ai Infrastructure And Financing Partnership With Vertical Data